Business Context and Reporting Period
This Form 8-K Current Report was filed by Atara Biotherapeutics, Inc. on September 12, 2018, covering events occurring on September 11, 2018. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new independent director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The Board of Directors increased its authorized size from seven to eight members, creating a vacancy.
- New Appointment: Roy Baynes, M.D., Ph.D., was appointed to fill the vacant seat. His initial term expires at the 2019 annual meeting of stockholders.
- Independence: The Board determined Dr. Baynes is independent under the Company's Corporate Governance Guidelines, SEC requirements, and Nasdaq listing standards.
- Committee Assignments: Dr. Baynes was not appointed to any Board committees at the time of filing.
Compensation and Arrangements
Dr. Baynes entered into standard non-employee director compensation arrangements effective September 11, 2018:
- Annual Retainer: $40,000, pro-rated for partial periods of service.
- Stock Option: An option to purchase 16,500 shares of Common Stock, vesting annually over three years contingent on continuous service.
- Indemnification: The Company entered into its standard form of indemnification agreement with Dr. Baynes.
Outlook, Risks, and Contingencies
The filing contains no management commentary regarding business outlook, risks, contingencies, or unusual items. It is a routine disclosure of a director appointment.
Investor Verification Checklist
- Verify Dr. Baynes' professional background and potential conflicts of interest via the Company's Proxy Statement.
- Confirm the vesting schedule and exercise price of the 16,500 share option grant.
- Review the Company's 2018 Proxy Statement for full details on the non-employee director compensation plan.
- Monitor future filings for Dr. Baynes' assignment to specific Board committees.